数据
资源
版本对比
免费注册
预约演示
免费注册
Reviva
to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of
Brilaroxazine
in
Schizophrenia
2024-02-06
·
BioSpace
临床3期
高管变更
并购
临床结果
孤儿药
CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) --
Reviva Pharmaceuticals Holdings, Inc.
(NASDAQ:RVPH) (“
Reviva
” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The
University of Texas
; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment. To register, click here. The event will focus on reviewing
Reviva
's positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily
brilaroxazine
in adults with
acute schizophrenia
, as well as the Company's ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial. A live question and answer session will follow the formal presentations. About Larry Ereshefsky, PharmD, BCPP, FCCP Larry Ereshefsky, PharmD, BCPP, FCCP, over his 45 years’ career, applies his experience as a clinician, scientist, and investigator, to develop treatments and innovate clinical methodologies to make a difference in the lives of patients with
Neurodegenerative and Psychiatric Disorders
. He has contributed significantly to several drug approvals spanning neurology and psychiatry, including drug development planning, PK/PD evaluation, and methodological innovation for
Schizophrenia
,
Depression
,
Bipolar Disorder
,
Parkinson’s (PD)
,
Alzheimer’s Diseases (AD)
, and
pain
indications. He has assisted in the design, implemented, supervised, and conducted more than 100 CNS clinical trials ranging from first into patient through to proof of concept, implements Asian Bridging strategies, and has overseen large global Phase III registration trials. He is a leader in the use of signal detection strategies to minimize placebo response. Larry has a proven track record as an investigator, translational CNS scientist, and clinical advisor in designing and performing Phase I/IIA and clinical pharmacology studies. He is a retired Regents Professor of Pharmacy, Psychiatry, and Pharmacology from The
University of Texas
/UT Health Science Center. Subsequently, he was the CSO (Chief Scientific Officer) and Exec VP for California Clinical Trials, acquired by
PAREXEL International
where his role was VP, Principal Pharmacologist and Therapeutic Area Leader for CNS Early Phase with Global responsibilities. Currently, he is the owner of Follow the Molecule:
CNS Consulting
, providing services to pharma, CROs, technology vendors, and minority owner in
ProScience Research Group
. He also served as Chief Science Officer for
APEX Innovative Sciences
(minority owner) including their 2 x 80 bed early phase research units (
CNS Network
, CA and Hassman Research Institute, NJ).
APEX
was recently bought by
CenExel Research
providing 18 clinical research sites designing, conducting, and supporting drug development from the earliest (FIH) to late-stage drug development across a variety of indications. As a leader in the application of translational drug development tools (including measuring neurocircuitry/biomarker/inflammatory signal via MRS, fMRI, electrophysiology, PET, CSF and PBMCs, and cognitive and behavioral paradigms), he helps de-risk drug development. As co-head of The Advanced Pharmacology and Evaluation Lab at
UT
, his team made pioneering contributions to understand the relationship of pharmacogenetics, drug interactions, and the environment upon the PK/PD of drugs. Dr. Ereshefsky’s unique perspective as a clinical scientist (clinical psychiatric pharmacist and psychopharmacologist) helps to guide drug development from preclinical to late Phase. He served twice on the FDA Psychopharmacological Drugs Advisory Committee. His PharmD and Residency in Psychopharmacology and Clinical Pharmacy were at the
University of Southern California
and LA County Medical Center and is Board Certified in Psychiatric Pharmacy. About Mark Opler, PhD, MPH Mark Opler, PhD, MPH holds the titles of Chief Research Officer at WCG Inc. and Executive Director of the PANSS Institute. Dr. Opler has served as a faculty member in the Departments of Psychiatry and Environmental Medicine at
New York University School of Medicine
and in the Department of Neuroscience at
Columbia University
,
College of Physicians and Surgeons
. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent
mental disorders
. He is a co-author and developer of several clinical assessment tools, including the SNAPSI, CGI-DS, and NY-AACENT. He is a contributor to the latest edition of the PANSS Manual©. Dr. Opler has received research support from the US NIMH, the Brain & Behavior Foundation (formerly NARSAD), the
Stanley Medical Research Institute
, and the Qatar National Research Fund. He has co-authored more than 50 peer-reviewed publications and has contributed to multiple book chapters and review articles on clinical assessment, research methodology, and mental health. He received his PhD and MPH from
Columbia University
and his BSc from SUNY at
Stony Brook
. He is a graduate of the Psychiatric Epidemiology Training Program at
Columbia University
and completed his postdoctoral fellowship at the
New York State Psychiatric Institute
. About
Brilaroxazine
Brilaroxazine
is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in
schizophrenia
and its comorbid symptoms. Positive topline data from the global Phase 3 RECOVER trial in
schizophrenia
demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of
brilaroxazine
vs. placebo with a generally well-tolerated side effect pro to placebo and discontinuation rates lower than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of
CYP3A4 enzyme
on
brilaroxazine
in healthy subjects supports no clinically significant interaction when combined with a
CYP3A4 inhibitor
CYP3A4
inhibitor.
Reviva
believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for
brilaroxazine
.
Reviva
intends to develop
brilaroxazine
for other neuropsychiatric indications including
bipolar disorder
,
major depressive disorder (MDD)
and
attention-deficit/hyperactivity disorder (ADHD)
. Additionally,
brilaroxazine
has shown promising nonclinical activity for
inflammatory diseases psoriasis
,
pulmonary arterial hypertension (PAH)
and
idiopathic pulmonary fibrosis (IPF)
with mitigation of
fibrosis
and
inflammation
in translational animal models.
Brilaroxazine
has already received Orphan Drug Designation by the U.S. FDA for the treatment of
PAH
and
IPF
conditions. To learn more about the clinical and preclinical data available for
brilaroxazine
, please visit revivapharma.com/publications. About
Reviva
Reviva
is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families.
Reviva
’s current pipeline focuses on the central nervous system,
respiratory and metabolic diseases
.
Reviva
’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and
RP1208
. Both are new chemical entities discovered in-house.
Reviva
has been granted composition of matter patents for both
brilaroxazine
and
RP1208
in the United States, Europe, and several other countries. Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle bmackle@lifesciadvisors.com Media Contact: Kristin Politi kpoliti@lifescicomms.com (646) 876-4783
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Reviva, Inc.
Reviva Pharmaceuticals Holdings, Inc.
The University of Texas at Austin
[+15]
适应症
精神分裂症
急性精神分裂症
神经系统变性病
[+14]
靶点
CYP3A4
药物
Brilaroxazine
CDK2 inhibitor (Relay Therapeutics)
RP-1208
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
第一三共ADC药物DS-8201专利调研实务指南
智慧芽生物医药
2024年3月全球首批及特殊审评药物报告
智慧芽生物医药
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务